{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:47:50Z","timestamp":1740134870663,"version":"3.37.3"},"reference-count":10,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3,31]]},"DOI":"10.1182\/blood.2021014678","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T22:45:14Z","timestamp":1648766714000},"page":"1928-1930","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Always be prepared for success"],"prefix":"10.1182","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1824-2337","authenticated-orcid":false,"given":"Jason","family":"Westin","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"13","key":"2022033115391547600_B1","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood.2021011894","article-title":"Phase 1\/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma","volume":"139","author":"Ward","year":"2022","journal-title":"Blood."},{"issue":"9","key":"2022033115391547600_B2","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2014-09-598763","article-title":"Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression","volume":"125","author":"Jacobsen","year":"2015","journal-title":"Blood."},{"issue":"22","key":"2022033115391547600_B3","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1002\/cncr.26135","article-title":"Higher response to lenalidomide in relapsed\/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype","volume":"117","author":"Hernandez-Ilizaliturri","year":"2011","journal-title":"Cancer."},{"key":"2022033115391547600_B4","doi-asserted-by":"crossref","first-page":"TPS7571","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS7571","article-title":"Brentuximab vedotin in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (trials in progress)","volume":"39","author":"Bartlett","year":"2021","journal-title":"J Clin Oncol."},{"issue":"9","key":"2022033115391547600_B5","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.3324\/haematol.2020.275958","article-title":"Long-term outcomes from the Phase\u00a0II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"106","author":"Duell","year":"2021","journal-title":"Haematologica."},{"issue":"13","key":"2022033115391547600_B6","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1182\/blood.2018891598","article-title":"Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed\/refractory non-germinal center B-cell-like DLBCL","volume":"134","author":"Goy","year":"2019","journal-title":"Blood."},{"key":"2022033115391547600_B7","first-page":"bloodadvances.2021005794","article-title":"Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory DLBCL: survival update and new extension cohort [published online ahead of print 8 November 2021]","author":"Sehn","year":"2021","journal-title":"Blood Adv."},{"issue":"6","key":"2022033115391547600_B8","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol."},{"issue":"12 Pt 2","key":"2022033115391547600_B9","first-page":"2648","article-title":"Freireich's laws in the treatment of sarcomas","volume":"3","author":"Benjamin","year":"1997","journal-title":"Clin Cancer Res."},{"year":"2021.","author":"Cavallo","key":"2022033115391547600_B10"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/13\/1928\/1884238\/bloodbld2021014678c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/13\/1928\/1884238\/bloodbld2021014678c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T22:45:20Z","timestamp":1648766720000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/139\/13\/1928\/484466\/Always-be-prepared-for-success"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":10,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2022,3,31]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021014678","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"subject":[],"published":{"date-parts":[[2022,3,31]]}}}